A Phase 2a, Single-Blind, Placebo-Controlled, Parallel-Group Study to Assess Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
Latest Information Update: 14 Nov 2023
At a glance
- Drugs Brensocatib (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Insmed
Most Recent Events
- 17 Jan 2023 Status changed from recruiting to completed.
- 12 Oct 2022 Planned number of patients changed from 48 to 34.
- 08 Mar 2022 Planned End Date changed from 7 Jun 2022 to 17 Apr 2023.